Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers

Status Completed

Clinical Trial Summary

This 18-week, randomized, double blind clinical trial provided treatment for 160 cocaine-dependent opioid addicts, aged 18-65 years. Participants were stabilized on LAAM maintenance during the first 4 weeks and cocaine use was assessed; participants were then stratified by level of cocaine use and randomly assigned to receive one of the following: placebo disulfiram (0 mg/day), disulfiram at 62.5 mg/day, disulfiram at 125 mg/day, or disulfiram at 250 mg/day. During induction onto LAAM, participants were administered increasing doses of LAAM plus placebo disulfiram on a thrice-weekly basis until maintenance doses of LAAM are attained. At the beginning of week 5, participants received LAAM plus disulfiram or placebo disulfiram according to their randomized assignments, and were maintained on these agents through week 16. At the end of the study, participants underwent detoxification from LAAM and active/placebo medication over a 4- to 6-week period. All participants received weekly 1-hour psychotherapy (Cognitive Behavioral Treatment) with experienced clinicians specifically trained to deliver the therapy and who received ongoing supervision. The primary outcomes were retention and reduction in opioid and cocaine use, as assessed by self-report and confirmed by thrice-weekly urinalyses. Secondary outcomes included reductions in other illicit drug and alcohol use, as well as improvements in psychosocial functioning.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00580827
Study type	Interventional
Source	Yale University
Contact
Status	Completed
Phase	N/A
Start date	September 2003

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03538444` - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder	N/A
Completed	`NCT01690546` - Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence	Phase 2
Completed	`NCT01442493` - Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment	N/A
Completed	`NCT01389167` - Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia	Phase 3
Completed	`NCT01182402` - Electronic Compliance Monitoring in Opioid Substitution Treatment	N/A
Completed	`NCT00987961` - Linking Hospitalized Injection Drug Users to Buprenorphine	Phase 3
Completed	`NCT00634803` - Clinical Trial of Integrated Treatment for Pain and Opioid Dependence	Phase 1/Phase 2
Completed	`NCT00577408` - Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone	Phase 3
Completed	`NCT00566969` - Cocaine Withdrawal and Pharmacotherapy Response	N/A
Completed	`NCT00539123` - Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia	N/A
Completed	`NCT00757744` - Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China	Phase 3
Recruiting	`NCT00241930` - Integrating Buprenorphine Into HIV Treatment	Phase 4
Completed	`NCT00218621` - The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1	Phase 2
Completed	`NCT00406484` - Brief Introductory Therapy for Opioid Dependence	Phase 2
Completed	`NCT03015597` - Pilot Study of Contingency Management for Smoking Cessation	N/A
Completed	`NCT01393392` - Developing a Smoking Cessation Intervention for Methadone Maintained Smokers	Phase 1
Completed	`NCT01416584` - A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment	N/A
Recruiting	`NCT00439049` - Substance Abuse Pre-Treatment Screening Study
Withdrawn	`NCT00398008` - HIV Risk Reduction and Drug Abuse Treatment in Iran	Phase 2
Completed	`NCT00622596` - Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance	N/A